Strategic partnerships Amprion has active collaboration with Mayo Clinic Laboratories and licensing deals with MLM Medical Labs, indicating a strong partner network and potential for co-marketing, white-label opportunities, or expansion through hospital and lab networks that can be leveraged for selling SAAmplify-ɑSYN tests.

Expanded testing capacity Recent financing from Decathlon Capital to expand diagnostic testing capacity suggests readiness to scale operations; sales teams can target large hospital systems and reference laboratories seeking validated neurodegenerative diagnostics to meet growing demand.

Global IP footprint Patents secured worldwide, including China and India, open doors for international distribution partnerships, licensing, and tiered pricing strategies to address emerging markets with high neurodegenerative disease prevalence.

Clinical adoption momentum Strategic initiatives to broaden access and a redesigned website following collaboration with Mayo Clinic Laboratories indicate increasing market adoption; opportunities exist in healthcare systems prioritizing early and accurate synucleinopathy diagnostics.

Evidence-driven target SAAmplify-ɑSYN test offers first-in-class LDT capability for multiple synucleinopathies, positioning Amprion to engage neurology departments and pathology labs with value-focused messaging around improved diagnostic clarity and potential for streamlined patient pathways.